Hello, everyone, and how are you today? We are doing just fine, thank you, given the circumstances. A clear blue sky and cool breezes are decorating the Pharmalot campus, where the short person is staring intently at a laptop and the official mascot is practicing his new-found bark at the neighbors. As for us, we are engaging in the usual routines — firing up the coffee kettle and digging about for interesting items. On that note, time to get cracking, yes? Hope your day goes well and you continue to manage. Chin up, as they say. …

Hospitals and physicians around the country are sharply criticizing the federal government for the uneven and opaque way it is distributing its supply of remdesivir, the Gilead Sciences (GILD) drug for Covid-19, STAT says. About two dozen hospitals are believed to have been chosen to receive the drug so far, but clinicians complain it is unclear why some medical centers were chosen to receive coveted doses while others were not — and who is making those decisions in the first place.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy